| WBD |
Report |
Q2 2026 Adjusted EPS |
MISS |
pred ~-$0.20 vs. cons -$0.13 |
MEDIUM |
| WBD |
Report |
Q2 2026 Total Revenue |
MISS |
pred ~$9.10B vs. cons $9.24B |
MEDIUM |
| WBD |
Report |
Streaming (HBO Max) Adjusted EBITDA |
BEAT |
pred ~$560M vs. cons $520M |
MEDIUM |
| WBD |
Guide |
FY2026 Adjusted EPS guidance/implied consensus path |
LOWER |
guide ~-$1.20 vs. cons -$1.07 (FY2026) |
MEDIUM |
| WBD |
Guide |
Global Streaming Subscribers target, YE2026 |
BETTER |
guide ~155M vs. cons 150M (YE2026) |
MEDIUM |
| WBD |
Guide |
Studios Adjusted EBITDA, FY2026 (vs. 2025 'in-line' framing) |
UNCHANGED |
guide ~$2.9B vs. cons $3.0B (FY2026) |
MEDIUM |
| WBD |
Guide |
Free Cash Flow conversion range |
UNCHANGED |
guide ~33%-50% vs. cons ~40% (FY2026) |
LOW |
| WBD |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| WBD |
Return |
5-day cumulative residual |
-0.7% (STABILIZE) |
Headline EPS miss is driven almost entirely by recognizable, non-recurring deal-related cash costs (advisory fees, bridge financing interest, tax leakage) rather than core deterioration, and Streaming EBITDA beat plus reaffirmed 150M+ subscriber trajectory should reassure on the standalone story; but Studios guidance staying merely 'in-line' with 2025 caps upward estimate revisions, so out-period numbers don't move much either way. With deal-question moratorium on the call and the Paramount litigation/trial timeline (paused to June 2027, trial March 2027) remaining the dominant driver of price action, the stock should stabilize near its post-print level over the following days rather than extending a large idiosyncratic move, as trading reverts to being driven by antitrust-litigation headlines rather than the quarter's fundamentals. |
LOW |